13 December 2016

Annual World Congress, Miami 2017 - Accepted abstract submissions

Ketul Choudhary

Oral presentations

We are delighted to inform the following abstracts have been selected to give an oral presentation. Presentations are scheduled in the Congress programme for Thursday 26 January 2017, 15:30 to 17:30 and Saturday 28 January 2017, 11:30 to 12:30. Further details about exact slots within these sessions will be published at a later time.

  • A Phase 2 Placebo-controlled, Randomized, Double-blind Clinical Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Pulsed, Inhaled Nitric Oxide (iNO) in Patients with WHO Group 1 Pulmonary Arterial Hypertension (PAH): 12 month interim analysis of open label extension
  • An Estrogen Receptor α (ERα)-BMPR2-Apelin Axis Mediates 17ß-Estradiol (E2)’s Protective Effects On Right Ventricular (RV) Function in Experimental Pulmonary Hypertension (PH)
  • Caveolin-1 loss/dysfunction may in part facilitate metabolic shift in pulmonary hypertension
  • Characterizing the Progression of PAH in the Left and Right Pulmonary Arteries of a PAH rat animal model
  • Clinical, laboratory, echocardiographic and hemodynamic characteristics in relation to survival in pulmonary arterial hypertension associated with congenital heart disease
  • Clinical, laboratory, echocardiographic and hemodynamic characteristics in relation to survival in pulmonary arterial hypertension associated with congenital heart disease
  • Colchicine-Induced Microtubule Depolymerization Increases Junctophilin-2 and Improves Right Ventricular Function in Experimental Pulmonary Arterial Hypertension Hypertension 
  • Comparing Survival in Pulmonary Hypertension due to Chronic Lung Disease with Pulmonary Arterial Hypertension
  • Development of new pre-clinical model of pulmonary hypertension associated with left heart disease.
  • Effects of riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) versus persistent/recurrent pulmonary hypertension (PH) after pulmonary endarterectomy (PEA): 2-year efficacy results from the CHEST-2 study
  • Effects of riociguat in treatment-naïve vs pretreated patients with pulmonary arterial hypertension (PAH): 2-year efficacy results from the PATENT-2 study
  • Endothelial Exosomes Induced by Aldosterone Increase Fibrillar Collagen Levels in Pulmonary Artery Smooth Muscle Cells
  • Evaluation of the Diagnostic and Prognostic Performance of Urinary Nitric Oxide In Children With Pneumonia
  • Feasibility of determining right ventricular diastolic stiffness from a standard right heart catheterization
  • HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension
  • Identifying components of the mitochondrial electron transport chain that mediate oxygen sensing in the pulmonary circulation: potential therapeutic targets for pulmonary hypertension
  • Improved platelet aggregation following administration of phosphodiesterase-5 inhibitors in patients with Eisenmenger syndrome
  • Increased interleukin-1 levels are an early hallmark of pulmonary remodelling in Fra-2 mouse model of scleroderma
  • Inhibiting PINK1-and PKA-mediated phosphorylation of mitofusin 2 prevents proteasomal degradation: A new mitofusin 2 construct displays enhanced efficacy in hyperproliferative diseases
  • Iron Deficiency in Hypoxic Pulmonary Hypertension Results in Increased Circulating Erythropoietin Which is Associated with Attenuated Pulmonary Hypertension
  • MicroRNA Biomarkers in Persistent Pulmonary Hypertension of the Newborn
  • Molecular Imaging of the Human Pulmonary Vascular Endothelium in Pulmonary Hypertension:  A Phase II Safety and Proof of Principle Trial
  • p22phox dependent NADPH oxidase in chronic obstructive pulmonary disease and pulmonary hypertension
  • PBI-4050 Therapy Selectively Improves Pulmonary Hypertension, Lung Remodeling and Right Ventricular Function in Heart Failure With Reduced Ejection Fraction (HFrEF)
  • Phosphoproteomic Analysis of Lung Tissue in Pulmonary Arterial Hypertension Reveals Activation of Immune Modulatory, Angiogenic, and Cell Proliferation Pathways
  • Pulmonary Hypertension in Interstitial Lung Disease: Ege University Experience
  • Reduction in CD68 macrophage number causes a spontaneous, and gender specific PAH phenotype in mice.
  • Relation of Right Ventricular Volumes and Strain using Three-Dimensional Echocardiography in Pediatric Pulmonary Hypertension
  • Right Ventricle on Fire: Interleukin-6 is Independently Associated with Right Ventricular Function in Pulmonary Arterial
  • Role of altered mitochondrial metabolism in right ventricular fibroblasts in determining fibrosis in the right ventricle in pulmonary arterial hypertension
  • Role of metabolic syndrome in pulmonary hypertension associated with left heart disease.
  • Sirt1 Activity is Necessary for the Protective Effects of the Female Sex in the Response to Chronic Hypoxia: A Role for Sirt1 in Estrogen Signaling
  • The Obesity Paradox in Pulmonary Hypertension: Observations from a Nationwide Inpatient Sample Database 2003-2011
  • The relationship between nitric oxide pathway biomarkers and response to riociguat in the RESPITE study of patients with pulmonary arterial hypertension (PAH) not reaching treatment goals with phosphodiesterase 5 inhibitors (PDE5i)
  • The Transpulmonary Ratio of Endothelin 1 is increased in Patients with Combined Pre- and Post-capillary Pulmonary Hypertension

Oral presentation specifications

  • Presentations are shorter than in traditional oral sessions. Each presenter gets 10 minutes: 5 min to present followed by 5 min for Questions & Answers.
  • PowerPoint slides are required.
  • Please email your PowerPoint slides to: Admin@pvri.info by 10 January 2017.


Moderated posters

The following abstracts are invited to participate in the moderated poster session, which is scheduled during lunch on Saturday 28 January 2017 from 13:00-14:00. Nominated experts will be there to facilitate poster discussions.

  • A Rare cause of Pulmonary Hypertension; Pulmonary artery involvement of Takayasu arteritis: 2 case in a single center experience
  • A Young Patient with Pulmonary Arterial Hypertension
  • Application of the criteria for satisfactory clinical response to riociguat treatment of patients with pulmonary arterial hypertension (PAH) in PATENT-1 and PATENT-2
  • Clinical and Hemodynamic Benefit of Macitentan and Riociguat Upfront Combination in Patients with PAH. 
  • Concentric RV remodeling represents an adaptive phenotype only in patients with advanced pulmonary arterial hypertension.
  • CT Measures of Intraparenchymal Arterial and Venous Volume Distribution in Pulmonary Hypertension
  • Derivation of New Formula Relating Pulmonary Acceleration Time & Mean Pulmonary Artery Pressure in Indian Population
  • Diastolic pressure gradient predicts operability in children with post tricuspid shunt and pulmonary arterial hypertension.
  • Discriminant validity of the six-minute walk distance for muscle weakness in patients with pulmonary arterial hypertension
  • Distinctive Clinical and Hemodynamic Characteristics of IPAH Patients of Indian Descent from Guyana 
  • Effect of Cigarette Smoking and Honey on Lung Inflammation by Lipopolysaccharide (LPS) in Mice
  • Endothelial response to cytokine stimulation is disturbed in Pulmonary Arterial Hypertension: Cilium length as a functional marker for dysregulated immunity.
  • Evaluation of health-related quality life in patients with pulmonary arterial hypertension
  • Evaluation of Pulmonary Perfusion Using an Endothelial Cell Tracer in Supine Humans and Dogs
  • Evaluation of tumor produced EMAP II as a T lymphocyte apoptosis inducing and potentially immune suppressive mechanism
  • Evolution of pulmonary pressure in healthy newborns, in the first three months of life, in Bogota, located at 2.640 meters over sea level (MOSL)
  • Experience in the follow-up of dual treatment in pediatric patients with pulmonary hypertension
  • Identification of novel BMP signaling regulator to attenuate pulmonary arterial hypertension
  • Improvement in Right Ventricular Dispersion after Inhalation of Iloprost in Pulmonary Hypertension
  • Increased Mitochondrial Motility in Pulmonary Arterial Smooth Muscle Cells in Pulmonary Arterial Hypertension
  • Incremental efficacy of an inhaled PDGFR inhibitor in combination with tadalafil and ambrisentan for the treatment of pulmonary arterial hypertension
  • Intravenous epoprostenolin pulmonary hypertension: experience of a single center
  • Is hypoxemia in the altitude -in young infants- related with neurologic respitatory control changes or secondary to an increase in the vascular pulmonary reactivity?
  • Lipopolysaccharides induce survival in lung cell lines – The role of protein-kinases activation
  • NADPH oxidase 4 is not involved in hypoxia-induced pulmonary hypertension
  • Not all Centrilobular Nodules are in the Airways: A case of intravascular birefringent polarizable material
  • Paradoxical impact of cholesterol on lipid packing and cell stiffness
  • Parallels between endothelin-1 receptor antagonists in pulmonary arterial hypertension and fetal development
  • Perioperative management of massive pulmonary hemorrhage after pulmonary endarterectomy
  • Preliminary Ambrisentan Tadalafil Combination Experience
  • Prognostic Value of the Baseline Serum Sodium Level in 2 Independent Cohorts of Pulmonary Arterial Hypertension
  • Pulmonary Arterial Hypertension in the Setting of Scleroderma is different than in the Setting of Lupus
  • Pulmonary artery pulse pressure is an independent predictor of mortality in who group ii pulmonary hypertension patients awaiting heart transplant
  • Pulmonary hypertension (PH) in children in altitude
  • Pulmonary Vascular effects after pulsed inhaled NO evaluated by Functional Respiratory Imaging (FRI)
  • Rapid Regulation of the G-Protein Coupled Receptor GPR55 by 2-Oxoglutarate Dependent Oxygenases in Pulmonary Endothelium
  • Real World Analysis of Riociguat Data (REWARD) for CTEPH from a Single Center. 
  • Riociguat for the treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH): Application of criteria for satisfactory clinical response to CHEST-1 and CHEST-2 populations
  • Role of female sex hormones in modulating the severe pulmonary arterial hypertension phenotype induced by VEGFR2 inhibition in a ‘hyper-responsive’ colony of Sprague Dawley rats
  • RVOT Velocity for predicting survival in patients with Pulmonary Hypertension
  • Selective Accumulation of Hsp90 in Mitochondria as an Adaptive Strategy to Face Stress in Pulmonary Arterial Hypertension
  • Sildenafil improves right ventricular function but does not ameliorate the reduced biologically active lung vasculature in pulmonary hypertension induced by hypoxia/sugen in rats
  • Single-center experience on rheolytic thrombectomy in patients with pulmonary embolism at high risk or intermediate-high risk
  • Swinging Between Group 1 and Group 2 Pulmonary Hypertension: A Case Presentation
  • The association of adiponectin and pulmonary hypertension in African-Americans: The Jackson Heart Study
  • The Importance of ECHO findings, RV/LV Ratio and Cardiac Biomarkers for Prognosis and Follow-Up in Patients with Pulmonary Embolism
  • The prognostic value of Qp/Qs ratio in pulmonary hypertension patients without left-to-right shunts
  • The Role of ECHO findings, RV/LV and Cardiac Biomarkers for Prognosis and Follow-Up in Patients with Pulmonary Embolism
  • Thromboembolic Prophylaxis with Rivaroxaban in Patients with Chronic Thromboembolic Pulmonary hypertension: A Single Tertiary Care Center Experience from Istanbul, Turkey
  • Transcriptional repressive and activation programs regulate alveolar epithelial cell fate and plasticity for lung alveolar generation.
  • Up-Regulation of FOXM1 in PAH Promotes DNA Repair and Cell Survival.


Moderated poster specifications

Posters should be brought to the Congress and must adhere to the following specifications:

  • Poster to be printed landscape:
  • Width: 180 cm
  • Height: 120 cm.


Abstract awards

The two Best Clinical Abstracts and the two Best Basic Abstracts will be announced at the Gala Dinner, as well as the winner of the Butrous Foundation Young Investigator Award for the overall best abstract.  Recipients of the Travel Grant Award will also be revealed.


Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI